Working… Menu

Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00296790
Recruitment Status : Completed
First Posted : February 27, 2006
Last Update Posted : October 12, 2007
Information provided by:

Brief Summary:
A comparison of Zolpidem Tartrate Extended-Release (Ambien CR)vs. Placebo in the Treatment of Insomnia Associated with Generalized Anxiety Disorder (GAD) when Used Concomitantly with Escitalopram (Lexapro - antidepressant).

Condition or disease Intervention/treatment Phase
Insomnia Drug: zolpidem tartrate Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 372 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : February 2006
Study Completion Date : February 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Primary Outcome Measures :
  1. Evaluate safety and hypnotic efficacy of zolpidem tartrate extended release vs. placebo in treatment of insomnia associated with Generalized Anxiety Disorder when used concomitantly with escitalopram

Secondary Outcome Measures :
  1. To show that treating insomnia from beginning of SSRI (Selective Serotonin Reuptake Inhibitor) treatment for anxiety results in improvement in quality of life and possibly greater response to anti-anxiety therapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  1. Male or female between the ages of 21and 64 years, inclusive;
  2. Women must use a medically acceptable form of contraception during the entire study period, or: be surgically sterilized, post-menopausal, agree to use double-barrier contraception throughout the study period, or must have a negative urine pregnancy test prior to randomization;
  3. Must meet the diagnostic requirements of Generalized Anxiety Disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders;
  4. Score at least 18 on the Hamilton Rating Scale for Anxiety (HAM-A)
  5. Must be either newly diagnosed or show symptoms of relapse during a period of no drug therapy for anxiety.
  6. Subject must experience sleep disturbances at least three nights per week, for at least one month prior to study entry, based on historical data.
  7. Subject must be stabilized on all long-term medication therapy for at least one month prior to study entry.


  1. History of Post-Traumatic Stress Disorder;
  2. Concomitant Major Depressive Disorder or Bipolar Disorder;
  3. Any abnormal pre-study laboratory values that require clinical intervention
  4. Shift work or requirement for a regular change in sleep schedule by at least six hours within the previous month.
  5. Pregnant or breastfeeding
  6. History of drug addiction, alcoholism, or drug abuse
  7. Currently using a benzodiazepine or SSRI or more than 2 days of use within the 28 days preceding randomization.
  8. A positive urine drug screen for compounds that would interfere with the assessment of a hypnotic.
  9. Use of prescription and non-prescription sedative drugs;
  10. Prior failure to respond to escitalopram therapy for anxiety
  11. The presence of any untreated or uncompensated clinically significant renal, endocrine, gastrointestinal, hepatic, respiratory, cardiovascular, other neurologic, hematologic, oncologic, immunologic, cerebrovascular disease or malignancy.
  12. History of sleep apnea
  13. History of myasthenia gravis
  14. Known hypersensitivity and/or allergy to or previous adverse experience with zolpidem or escitalopram or any of their excipients
  15. Subject is currently participating in another clinical trial (or within 28 days of screening).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00296790

Layout table for location information
United States, New Jersey
Bridgewater, New Jersey, United States, 08807
Sponsors and Collaborators
Layout table for investigator information
Study Director: Phyllis Diener Sanofi
Layout table for additonal information Identifier: NCT00296790    
Other Study ID Numbers: PM_L_0167
First Posted: February 27, 2006    Key Record Dates
Last Update Posted: October 12, 2007
Last Verified: October 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action